A Phase 1, Open-Label Study of the Safety, Pharmacokinetics and Pharmacodynamics of JNJ-64457107, an Agonistic Human Monoclonal Antibody Targeting CD40 in Patients With Advanced Stage Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 11 Dec 2017
At a glance
- Drugs ADC 1013 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Janssen Research & Development
- 06 Dec 2017 Planned End Date changed from 15 Dec 2019 to 1 Oct 2019.
- 06 Dec 2017 Planned primary completion date changed from 7 Jan 2019 to 1 Jan 2019.
- 25 Oct 2017 According to an Alligator Bioscience media release, this study is ongoing with approximately 50 patients recruited to date.